Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes.

Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes.

Bibliographic Details
Main Authors:	Munro, N, Levy, J
Format:	Journal article
Language:	English
Published:	2007

Similar Items

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes
by: Catherine A Schnabel, et al.
Published: (2006-03-01)

Mechanisms of neuroprotective action of incretin mimetics
by: Timur Dmitrievich Vlasov, et al.
Published: (2016-01-01)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
by: Knop FK, et al.
Published: (2010-05-01)

Gemigliptin: Newer promising gliptin for type 2 diabetes mellitus
by: Manish Gutch, et al.
Published: (2017-01-01)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review
by: Katrine B Hansen, et al.
Published: (2010-05-01)

Incretin Mimetics in the Indian Context: Revisiting Exenatide
by: Shambo S Samajdar, et al.
Published: (2022-08-01)

Choosing a Gliptin
by: Vishal Gupta, et al.
Published: (2011-01-01)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
by: J Muthukrishnan, et al.
Published: (2012-01-01)

What the future holds for gliptins
by: Radhika Jindal, et al.
Published: (2012-01-01)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
by: Geke Aline Boer, et al.
Published: (2020-12-01)

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
by: Joan Khoo, et al.
Published: (2009-08-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
by: N. A. Petunina, et al.
Published: (2017-12-01)

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
by: Nicola Marrano, et al.
Published: (2021-02-01)

Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
by: Jared Rosenberg, et al.
Published: (2021-09-01)

Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs
by: Dariusz Popiela, et al.
Published: (2025-01-01)

Incretin hormones as immunomodulators of atherosclerosis
by: Nuria eAlonso, et al.
Published: (2012-09-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

Drug-induced bullous pemphigoid secondary to gliptin
by: Suvesh Singh, et al.
Published: (2024-01-01)

Acute pancreatitis with gliptins: Is it a clinical reality?
by: Muthukrishnan Jayaraman, et al.
Published: (2013-01-01)

Prescribing gliptins: Enthusiasm should be coupled with caution
by: M K Garg, et al.
Published: (2012-01-01)

CARDIOPRODUCTIVE EFFECTS OF EXXENATE AMID AND VILDAGLIPTIN INCRETIN MIMETICS IN DOXYRUBRICINE CARDIOMYOPATHY MODELING
by: A. P. TARASOVА, et al.
Published: (2017-09-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

The effects of incretin mimetics on the level of the microbial metabolite trimethylamine-N-oxide, a marker of cardiovascular risk in type 2 diabetic patients
by: K.O. Shyshkan-Shyshova, et al.
Published: (2023-11-01)

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
by: Dana Shalmon, et al.
Published: (2024-04-01)

Role of incretin‐based therapy in hospitalized patients with type 2 diabetes
by: Abraham Edgar Gracia‐Ramos
Published: (2020-03-01)

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
by: Jae Hyun Bae, et al.
Published: (2025-02-01)

Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus
by: Stanchev Pavel E., et al.
Published: (2019-03-01)

Understanding the Cardiovascular Effects of Incretin
by: Ji Sung Yoon, et al.
Published: (2011-10-01)

Role of incretins in the pathogenesis of type 2 diabetes
by: Radojčin Dragan, et al.
Published: (2018-01-01)

Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials
by: Mahmoud Barbarawi, et al.
Published: (2018-11-01)

Abnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus
by: T. Y. Demidova, et al.
Published: (2022-03-01)

New prospects for incretin‐related drugs in the treatment of type 2 diabetes
by: Tomohiko Kimura, et al.
Published: (2021-07-01)

Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review
by: Teodor Salmen, et al.
Published: (2024-10-01)

Oxytocin May be Superior to Gliptins as a Potential Treatment for Diabetic COVID-19 Patients
by: Phuoc-Tan Diep
Published: (2021-01-01)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
by: Stanley Schwartz, et al.
Published: (2010-07-01)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
by: Schwartz S
Published: (2010-07-01)

Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
by: Lili Liu, et al.
Published: (2019-03-01)

Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
by: Akira Mima
Published: (2016-01-01)